Vytrus selected for the BIOMED ScaleUP of CataloniaBio
The health industry has undergone a great evolution since 2010. According to the 2020 Catalonia BioRegion Report, 92% of the companies are micro and SMEs. Due to this, CataloniaBio has created the BIOMED ScaleUp program, with the aim of helping companies in the Catalan health and science sector grow and consolidate to increase their competitiveness at a global level.
According to Jordi Rovira, Vytrus CFO: “Our company, after a process of transformation and consolidation, has gone from being a start-up to becoming a fully industrial company today. This program represents an opportunity for Vytrus to continue growing and increasing our competitiveness internationally. “
BIOMED ScaleUp is expected to contribute to the business’ positive evolution with a consecutive turnover increase in the range of 30-40% in the last 3 years. The company foresees positive results for 2020 financial year, just awaiting for the external financial audit.
The CataloniaBio programm is a commitment both to the growth of companies that have passed the early-stage, and organizations that are in the international expansion phase such as Vytrus. This initiative seeks to promote companies in the health and life sciences sector in Catalonia that stand out for their growth potential in terms of innovation, processes, or market diversification.
The program consists of a first informative session by Melqui Calzado, general secretary of CataloniaBio & HealthTech, and the conference “How to prepare the company for growth” given by Xavier Marcet, consultant in strategy, innovation, and corporate entrepreneurship. After passing the first phase of 3 training capsules of corporate growth training and an individual diagnostic session -to assess the suitability of the company to participate in the program-, the next phase of personalized acceleration is accessed, with ten training capsules – on leadership, growth in different areas of the company, management, and differentiation, among others- and ten advisory sessions for the ten selected companies.
According to the latest Bioregion report, the biotech sector represents 7.3% of Catalan GDP, with a turnover of almost €20,000M, positioning as the second sector with the highest income in the ranking. BIOMED ScaleUp is one of the actions that is part of the strategic axis of promoting a cluster of high added value.